Topline data anticipated in early 2023NEW ORLEANS and LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the…
Paper published in the November 2022 issue of Podiatry Management(Robert J. Snyder, DPM, Cyaandi Dove, DPM, and Vickie Driver, DPM,…
Kabuki Syndrome Foundation Annual Conference11th Drug Discovery Strategic SummitInv€$tival Showcase LSX Leaders 2022Jefferies London Healthcare Conference 2022MADRID, Spain and BOSTON,…
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points…
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase…
New data from clinical trials of TT11 and TT11X to be featured in two oral podium presentations and a poster…
Interim data from phase III HAVEN 7 study reinforce Hemlibra’s efficacy and safety in infants with severe haemophilia A without…
Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignanciesSAN FRANCISCO,…
Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30…
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed…